Reisekonsortium fra TSS vinner BRITISH TRAVEL AWARD 2024 - Stor glede over anerkjent internasjonal utmerkelse
RSD Travel, den engelske søsterselskapet til TSS, er blant de tre beste studietur-arrangørene i Storbritannia. Slik er resultatet av en mye omtalt utmerkelse fra British Travel Awards (BTA) for året 2024.
De anerkjente BTA-reiseprisene er resultatet av den største forbrukerundersøkelsen i Storbritannia. Mer enn 409.000 feriegjester ga rundt 1,2 millioner stemmer, og det for mange, svært differensierte reisekategorier. Disse er hvert år delt inn etter geografiske regioner og fremfor alt: etter de forskjellige reisetypene.
Vurderingsrepertoaret strekker seg fra "familieferier", "singlereiser" eller "all inclusive" til "wildlife" eller "Art & Culture", altså de kulturelt pregede studiereiser. Nettopp her la RSD Travel - sammen med to andre leverandører - alle andre konkurrenter bak seg på det store britiske reisemarkedet.
For RSD, som også inkluderer TSS i sin reiseklynge og som er en av Europas ledende studieturreiser, er denne anerkjennelsen også viktig fordi et enormt antall reisende har gitt sin stemme for det. Administrerende direktør Horst Zsifkovits: "Arbeidet til mitt dedikerte team, den globale innsatsen til våre erfarne reiseledere, vårt uslåelige pris-ytelsesforhold, alt dette har folkene verdsatt på en fantastisk måte. Vi er veldig glade!
Kontakt
Telefon: +47 23 96 33 35
e-post: info@tss-travel.no
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site29.4.2025 14:00:00 CEST | Press release
The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals.
Bertelsmann Stiftung: Growth and innovation as cornerstones of a strong de-mocracy and a digitally sovereign Europe29.4.2025 12:00:00 CEST | Press release
Germany should be restored to a growth path and should give new impulse to innovation, along with its European partners. Because prosperity is a significant guarantor of a stable democracy. Digital sovereignty is the anchor of a strong Europe. Germany can once again be a country of pioneering innovation and a pacesetter for the continent. For this, comprehensive modernization of the state is indispensable. The Bertelsmann Stiftung presented its proposals at the annual press conference.
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study29.4.2025 09:00:00 CEST | Press release
Tübingen, Germany, April 29, 2025 Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Australia’s next government must mend structural cracks appearing in its political, economic and social foundation, report finds28.4.2025 08:33:05 CEST | Press release
Australia boasts some of the world’s most sophisticated political institutions and one of its wealthiest economies. But this veneer of success masks deeper structural issues — and a “ticking time bomb” of overreliance on extractive industries must be addressed under Australia’s next government, a new report recommends.
EOPA Best Business Product of the Year 2025 - DYMO LetraTag 200B (Source:OPI)25.4.2025 08:00:04 CEST | Press release
DYMO® LETRATAG 200B WINS PRESTIGIOUS “BUSINESS PRODUCT OF THE YEAR” AWARD - REINFORCING RISE OF SMART ORGANIZATION
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom